DULUTH, Ga., April 24, 2023 /PRNewswire/ -- Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has approved the newest addition to its feline portfolio — NexGard® COMBO (esafoxolaner, eprinomectin, and praziquantel topical solution). It is the first-and-only feline broad-spectrum protection against fleas, ticks, roundworms, hookworms, heartworm disease and tapeworms. NexGard® COMBO is a one-and-done, monthly topical solution, specially formulated for feline patients, that helps make compliance easy.
Zhejiang Hisun Pharmaceutical, Co., Ltd. (Yantou Campus) Fails EDQM Inspection